Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bas J M Peters

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Anticancer Research|December 27, 2017
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch PopulationRomina Sluga, Ben E E M VAN DEN Borne, Paul Roepman, et al.
Pharmacogenetics and Genomics|November 2, 2010
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarctionBas J M Peters, Andrei S Rodin, Olaf H Klungel, et al.
European Journal of Hospital Pharmacy : Science and Practice|February 24, 2022
The potential for deprescribing in a palliative oncology patient population: a cross-sectional studyLisanne N van Merendonk, Bas J M Peters, Julia E Möhlmann, et al.
Pharmacoeconomics - Open|June 14, 2020
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014Christine M Cramer-van der Welle, Bas J M Peters, Maarten J Deenen, et al.
Cancer Epidemiology|October 1, 2017
Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008-2012Bas J M Peters, Christine M Cramer-Vd Welle, Arthur A J Smit, et al.
Clinical Lung Cancer|February 13, 2025
Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer PatientsMarjon V Verschueren, Dagmar T A Hiensch, Peter M J Plomp, et al.
British Journal of Clinical Pharmacology|September 30, 2025
Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case seriesJeroen P A Houwen, Aurelia H M de Vries Schultink, Bas J M Peters, et al.
Scientific Reports|September 26, 2020
Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the NetherlandsDaan J Reesink, Ewoudt M W van de Garde, Bas J M Peters, et al.
Pharmacogenomics|February 22, 2011
CYP2C19 and ABCB1 genes and individualized treatment with clopidogrelBas J M Peters, Ankie M Harmsze, Jurriën M ten Berg, et al.
The European Respiratory Journal|November 30, 2018
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancerChristine M Cramer-van der Welle, Bas J M Peters, Franz M N H Schramel, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Anticancer Research|December 27, 2017
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch PopulationRomina Sluga, Ben E E M VAN DEN Borne, Paul Roepman, et al.
Pharmacogenetics and Genomics|November 2, 2010
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarctionBas J M Peters, Andrei S Rodin, Olaf H Klungel, et al.
European Journal of Hospital Pharmacy : Science and Practice|February 24, 2022
The potential for deprescribing in a palliative oncology patient population: a cross-sectional studyLisanne N van Merendonk, Bas J M Peters, Julia E Möhlmann, et al.
Pharmacoeconomics - Open|June 14, 2020
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014Christine M Cramer-van der Welle, Bas J M Peters, Maarten J Deenen, et al.
Cancer Epidemiology|October 1, 2017
Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008-2012Bas J M Peters, Christine M Cramer-Vd Welle, Arthur A J Smit, et al.
Clinical Lung Cancer|February 13, 2025
Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer PatientsMarjon V Verschueren, Dagmar T A Hiensch, Peter M J Plomp, et al.
British Journal of Clinical Pharmacology|September 30, 2025
Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case seriesJeroen P A Houwen, Aurelia H M de Vries Schultink, Bas J M Peters, et al.
Scientific Reports|September 26, 2020
Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the NetherlandsDaan J Reesink, Ewoudt M W van de Garde, Bas J M Peters, et al.
Pharmacogenomics|February 22, 2011
CYP2C19 and ABCB1 genes and individualized treatment with clopidogrelBas J M Peters, Ankie M Harmsze, Jurriën M ten Berg, et al.
The European Respiratory Journal|November 30, 2018
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancerChristine M Cramer-van der Welle, Bas J M Peters, Franz M N H Schramel, et al.
Pageof 4